Amoy Diagnostics Co., Ltd.

Equities

300685

CNE1000034D3

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 17/07/2024 am IST			5-day change	1st Jan Change
18.91 ^CNY	+2.00%		+5.41%	-13.97%

02/07	Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on April 1, 2024.	CI
13/06	Amoy Diagnostics Gets Certificate to Register PCR Analyzer	MT

Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on April 1, 2024.

July 02, 2024 at 06:24 pm IST

From April 1, 2024 to June 30, 2024, the company has repurchased 1,908,740 shares, representing 0.48% for CNY 36.47 million. With this, the company has completed the repurchase of 2,086,840 shares, representing 0.52% for CNY 40.24 million under the buyback announced on April 1, 2024.

Latest news about Amoy Diagnostics Co., Ltd.

Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on April 1, 2024.	02/07	CI
Amoy Diagnostics Gets Certificate to Register PCR Analyzer	13/06	MT
Amoy Diagnostics Co., Ltd. Announces Cash Dividend on A Shares for the Year 2023, Payable on 30 May 2024	25/05	CI
Amoy Diagnostics Co., Ltd. Approves Final Cash Dividend for 2023	15/05	CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	22/04	CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	15/04	CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on April 1, 2024.	01/04	CI
Amoy Diagnostics Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.	01/04	CI
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component A Share Index	11/12	CI
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component Index	11/12	CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23/23/23	CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	31/23/31	CI
Amoy Diagnostics to Collaborate with AstraZeneca Unit for Ovarian Cancer Companion Diagnostic in China	26/23/26	MT
Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023	17/23/17	CI
Amoy Diagnostics Co., Ltd. Approves Final Dividend for 2022	13/23/13	CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	21/23/21	CI
Amoy Diagnostics Co., Ltd. Proposes Final Cash Dividend for the Year 2022	18/23/18	CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	14/23/14	CI
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. and Precision Medicine Asia Co., Ltd. Announces the Japanese Ministry of Health, Labour and Welfare Approval in Japan as a Companion Diagnostic for Ret Fusion-Positive NSCLC	27/23/27	CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.	14/23/14	CI
Amoy Diagnostics Co., Ltd.'s Equity Buyback announced on February 13, 2023 has expired with 3,943,726 shares, representing 1% for CNY 112.01 million.	13/23/13	CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.	03/23/03	CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	24/22/24	CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.	10/22/10	CI
Alercell® to Distribute Amoydx® Ros1 Gene Fusion Detection Kit	08/22/08	CI

Chart Amoy Diagnostics Co., Ltd.

Duration

Period

More charts

Company Profile

Amoy Diagnostics Co Ltd is a pharmaceutical company engaged in research, development, production and sales of molecular diagnostic products. The Company provides testing reagents and testing services for tumor diagnosis. The Companyâs testing reagent products include ADx-ARMS product line for tumor tissue specimen detection, Super-ARMS product line for liquid biopsy, the NGS product line and the FISH product line. The products are used for the detection of non-small cell lung cancer, colorectal cancer, thyroid cancer, melanoma and other malignant tumors. The Company also provides data software to capture and analyze gene sequencing data. The Company provides testing services through its own medical testing institutions, including lung cancer testing, colorectal cancer testing and breast cancer testing.

Sector

Medical Equipment, Supplies & Distribution

Calendar

30/07/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Amoy Diagnostics Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

18.91 CNY

Average target price

28.6 CNY

Spread / Average Target

+51.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
AMOY DIAGNOSTICS CO., LTD.	-13.97%	1.01B
BIOMÉRIEUX	-6.61%	12.07B
LANTHEUS HOLDINGS, INC.	+96.15%	8.2B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-18.38%	6.59B
DIASORIN S.P.A.	+9.13%	5.89B
AUTOBIO DIAGNOSTICS CO., LTD.	-21.66%	3.47B
ANDON HEALTH CO., LTD.	+5.36%	2.52B
MYRIAD GENETICS, INC.	+41.54%	2.48B
VITROLIFE AB	+17.72%	2.3B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-18.43%	1.58B

Diagnostic & Testing Substances